P1, N=165, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting | N=100 --> 165 | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026

9 months ago

Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases

HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

HER-2 negative • ER negative • PGR negative

INCA33890

12ms

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)

P1, N=100, Not yet recruiting, Incyte Corporation

12 months ago

New P1 trial • Metastases

HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

HER-2 negative • ER negative • PGR negative

INCA33890

1year

INCA33890, a novel PD-1×TGFꞵR2 bispecific antibody conditionally antagonizes TGFꞵ signaling in primary immune cells co-expressing PD-1 (AACR 2023)

Additionally, in two independent PD-1 reporter assays, INCA33890 inhibited SHP recruitment and enhanced NFAT activation with a potency within an order of magnitude to that of pembrolizumab. Collectively, these results provide compelling data for an effective and specific approach to simultaneously antagonizing TGFβ and PD-1 signaling in tumors. Clinical development of INCA33890 in checkpoint inhibitor-resistant and other cancers has been initiated.

1 year ago

PD(L)-1 Biomarker • IO biomarker • Immune cell

PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CD34 (CD34 molecule) • TGFBR2 (Transforming Growth Factor Beta Receptor 2)

Keytruda (pembrolizumab) • INCA33890